“No Sputum, No Problem”: AveloMask Cystic Fibrosis Study Presented at DZIF Meeting
- Feb 25
- 1 min read
Updated: Feb 26
February 25, 2026. Avelo AG is pleased to announce that results from a clinical study evaluating the AveloMask Kit for detection of Pseudomonas aeruginosa in adults with Cystic Fibrosis (CF) were presented at the DZIF Annual Meeting in Bonn by researchers from Heidelberg University Hospital.
The study assessed non-invasive exhaled breath aerosol sampling using the AveloMask Kit as an alternative to sputum collection. New, highly effective CFTR-modulator therapies significantly reduce sputum production in people with CF, making alternative sampling approaches an urgent unmet need. The findings highlight the potential of AveloMask as a patient-friendly alternative for respiratory pathogen detection in CF, particularly for individuals who have difficulty producing sputum.
View the study results presented at DZIF 2026:
About Avelo
Avelo AG, the Swiss breath sampling company, aims to revolutionize the diagnosis of lower respiratory tract infections. Its breath collection device enables non-invasive collection of pathogens from breath aerosols and works with existing PCR tests. The novel device is designed for broad utility, similar to other sample collection technologies such as blood tubes.
Comments